Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Sophie Park

Sophie Park

MD, PhD
CHU Grenoble Alpes
The EPO-Pretar trial: early versus late onset of ESA in LR-MDS 4:21
The EPO-Pretar trial: early versus late onset of ESA in LR-MDS
Sophie Park • 9 Dec 2024
The LODEFI trial: low-dose deferasirox in LR-MDS resistant or relapsing after ESAs 2:12
The LODEFI trial: low-dose deferasirox in LR-MDS resistant or relapsing after ESAs
Sophie Park • 9 Dec 2024
Novel targets in low-risk MDS 1:27
Novel targets in low-risk MDS
Sophie Park • 22 Sep 2021
Assessing response to ESAs and alternative therapies 5:25
Assessing response to ESAs and alternative therapies
Sophie Park • 22 Sep 2021
ESAs for the management of lower-risk MDS 2:37
ESAs for the management of lower-risk MDS
Sophie Park • 22 Sep 2021
The content of VJHemOnc is intended for healthcare professionals